Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?
Abstract As pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered....
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-03-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13193 |
| _version_ | 1819002780084338688 |
|---|---|
| author | Karen M. Meagher Kelsey Stuttgen Finn Susan H. Curtis Jack Borucki Annika T. Beck Amal W. Cheema Richard R. Sharp |
| author_facet | Karen M. Meagher Kelsey Stuttgen Finn Susan H. Curtis Jack Borucki Annika T. Beck Amal W. Cheema Richard R. Sharp |
| author_sort | Karen M. Meagher |
| collection | DOAJ |
| description | Abstract As pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered. To characterize biobank participants’ understanding of PGx research results, we conducted a focus group study, which took place after PGx variants conferring increased risk of dihydropyrimidine dehydrogenase (DPD) deficiency were disclosed to biobank contributors. DPD deficiency confers an increased risk of adverse reaction to commonly used cancer chemotherapeutics. Ten focus groups were conducted, ranging from two to eight participants. Fifty‐four individuals participated in focus groups. A framework approach was used for descriptive and explanatory analysis. Descriptive themes included participants’ efforts to make sense of PGx findings as they related to: (1) health implications, (2) drugs, and (3) genetics. Explanatory analysis supplied a functional framework of how participant word choices can perform different purposes in PGx communication. Results bear three main implications for PGx research‐related disclosure. First, participants’ use of various terms suggest participants generally understanding their PGx results, including how positive PGx results differ from positive disease susceptibility genetic results. Second, PGx disclosure in biobanking can involve participant conflation of drug‐gene interactions with allergies or other types of medical reactions. Third, the functional framework suggests a need to move beyond a deficit model of genetic literacy in PGx communication. Together, findings provide an initial evidence base for supporting bidirectional expert‐recipient PGx results communication. |
| first_indexed | 2024-12-20T23:10:32Z |
| format | Article |
| id | doaj.art-cdfb92789b4943cd9e00a8a1e4faa8db |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-12-20T23:10:32Z |
| publishDate | 2022-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-cdfb92789b4943cd9e00a8a1e4faa8db2022-12-21T19:23:46ZengWileyClinical and Translational Science1752-80541752-80622022-03-0115372173110.1111/cts.13193Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?Karen M. Meagher0Kelsey Stuttgen Finn1Susan H. Curtis2Jack Borucki3Annika T. Beck4Amal W. Cheema5Richard R. Sharp6Biomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USABiomedical Ethics Research Program Mayo Clinic Rochester Minnesota USAAbstract As pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered. To characterize biobank participants’ understanding of PGx research results, we conducted a focus group study, which took place after PGx variants conferring increased risk of dihydropyrimidine dehydrogenase (DPD) deficiency were disclosed to biobank contributors. DPD deficiency confers an increased risk of adverse reaction to commonly used cancer chemotherapeutics. Ten focus groups were conducted, ranging from two to eight participants. Fifty‐four individuals participated in focus groups. A framework approach was used for descriptive and explanatory analysis. Descriptive themes included participants’ efforts to make sense of PGx findings as they related to: (1) health implications, (2) drugs, and (3) genetics. Explanatory analysis supplied a functional framework of how participant word choices can perform different purposes in PGx communication. Results bear three main implications for PGx research‐related disclosure. First, participants’ use of various terms suggest participants generally understanding their PGx results, including how positive PGx results differ from positive disease susceptibility genetic results. Second, PGx disclosure in biobanking can involve participant conflation of drug‐gene interactions with allergies or other types of medical reactions. Third, the functional framework suggests a need to move beyond a deficit model of genetic literacy in PGx communication. Together, findings provide an initial evidence base for supporting bidirectional expert‐recipient PGx results communication.https://doi.org/10.1111/cts.13193 |
| spellingShingle | Karen M. Meagher Kelsey Stuttgen Finn Susan H. Curtis Jack Borucki Annika T. Beck Amal W. Cheema Richard R. Sharp Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? Clinical and Translational Science |
| title | Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? |
| title_full | Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? |
| title_fullStr | Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? |
| title_full_unstemmed | Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? |
| title_short | Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words? |
| title_sort | lay understandings of drug gene interactions the right medication the right dose at the right time but what are the right words |
| url | https://doi.org/10.1111/cts.13193 |
| work_keys_str_mv | AT karenmmeagher layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT kelseystuttgenfinn layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT susanhcurtis layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT jackborucki layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT annikatbeck layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT amalwcheema layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords AT richardrsharp layunderstandingsofdruggeneinteractionstherightmedicationtherightdoseattherighttimebutwhataretherightwords |